Medpace Hit With Securities Fraud Lawsuit Over Alleged Misrepresentation of Cancellation Rates and Book-to-Bill

What happened

A class-action lawsuit has been filed against Medpace Holdings, alleging the company understated cancellation rates and overstated its book-to-bill ratio, leading to a 16% single-day stock drop. The suit, announced by Bleichmar Fonti & Auld LLP, claims the company misled investors about the health of its backlog and new business awards. The DeepValue report had already flagged cancellation rates and book-to-bill as critical watch items, noting that any deterioration would challenge Medpace's premium valuation. While Medpace's underlying business remains cash-generative with no debt, the lawsuit introduces legal risk and potential reputational damage that could further pressure the stock. Investors must now weigh the company's solid fundamentals against the uncertainty of litigation and potential restatements.

Implication

Investors should expect continued volatility as the lawsuit unfolds, with the June 8 deadline for lead plaintiff motions potentially drawing in more claimants. The core operational thesis from the DeepValue report remains intact—Medpace has strong cash flow and no debt—but the legal overhang could delay backlog conversion and dampen new awards as sponsors assess stability. The premium multiple (36.9x TTM P/E) leaves little room for error, and any adverse discovery or settlement could erode margins or require financial provisions. Long-term investors may want to reduce exposure until the cancellation rates and book-to-bill allegations are resolved, while speculators could trade the volatility. The risk/reward has shifted to unfavorable near term, supporting a downgrade from HOLD to SELL until more clarity emerges.

Thesis delta

The DeepValue report's neutral stance hinged on sustained book-to-bill above 1x and low cancellations. The fraud lawsuit directly challenges these metrics, alleging they were misrepresented, which undermines the credibility of recent operational data. This shifts the thesis from cautious neutral to outright bearish near term, as legal risk and potential restatements cloud the outlook.